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Abstract
Background: How to address the counseling of lifetime risk of developing Parkinson’s disease in patients with
Gaucher disease and their family members carrying a single variant of the GBA1 gene is not yet clearly defined. In
addition, there is no set way of managing Gaucher disease patients, taking into account the possibility that they
may show features of Parkinson’s disease.
Methods: Starting from an overview on what has recently changed in our knowledge on this issue and grouping the
experiences of healthcare providers of Gaucher disease patients, we outline a path of counseling and management of
Parkinson’s disease risk in Gaucher disease patients and their relatives.
Conclusion: The approach proposed here will help healthcare providers to communicate Parkinson’s disease risk to
their patients and will reduce the possibility of patients receiving inaccurate information from inadequate sources.
Furthermore, this resource will help to empower healthcare providers to identify early signs and/or symptoms of
Parkinson’s disease and decide when to refer these patients to the neurologist for appropriate specific therapy and
follow-up.
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Background
Gaucher disease (GD) is an inherited metabolic disorder
caused by biallelic mutations in the GBA1 gene. GBA1 en-
codes the glucocerebrosidase (GCase) enzyme, which ca-
talyses the hydrolysis of glucosylceramide into ceramide
and glucose. Macrophages engorged with aberrant lyso-
somes, as a result of the GCase-impaired activity (Gaucher
cells), infiltrate into the reticuloendothelial system of the
affected organs [1].
GD type 1, which accounts for up to 95% of patients
with GD in Europe and America, is typically considered
a systemic disorder, without neurological involvement.
Anaemia, leukopenia, thrombocytopenia with frequent
bleeding, hepatosplenomegaly, osteopenia with bone
pain, easy fractures, failure to grow and delayed puberty,
bone marrow infiltration with bone medullary infarcts
and osteonecrosis are the main features of this disease.
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Some GD patients with systemic disorder associated
with neurological involvement are usually reported as af-
fected with neuronopathic GD (GD type 2 and 3) [2].
The required criterion for the definition of neurono-
pathic GD is gaze palsy, predominantly horizontal, with
slow or absent saccades. Some neuronopathic GD pa-
tients only show this sign, whilst others show different
neurological abnormalities including cognitive impair-
ment, ataxia, hyperreflexia, spasticity, cerebellar or
action tremor, stridor, dysphagia, dysarthria, dystonia,
seizures and progressive myoclonic epilepsy [3].
Age of onset at 6 months, rapid deterioration in the
first 2 years of life and death by 4 years of age are charac-
teristic of acute neuronopathic GD (GD type 2), whereas
a later onset and neurological deterioration occurring
only in subjects with the progressive myoclonic epilepsy
variant are characteristic of chronic neuronopathic GD
(GD type 3) [3].
Adult onset Parkinson’s disease (PD), multiple system
atrophy and dementia with Lewy bodies are not features
of neuronopathic GD [3]. However, it has been shown
that the individuals with GD have an increased risk of
developing PD compared to the general population [4,
5]. PD is a progressive neurodegenerative disorder char-
acterised by several motor and non-motor signs and
symptoms with a mean onset at 50–60 years of age. PD
is primarily due to the degeneration of the midbrain
dopaminergic neurons, however, in the later stage of the
disease, the neuropathology may affect several different
areas of the nervous system [6].
The diagnosis of PD is based on clinical criteria in-
cluding rest tremor, rigidity, bradykinesia and a good re-
sponse to levodopa intake. Other clinical features either
motor (e.g., hypomimia, dysarthria, dysphagia, sialorrhea,
shuffling gait, postural instability, festination, freezing,
dystonia and micrographia), or non-motor (e.g., sleeping
disorders, hyposmia, autonomic dysfunction and cogni-
tive/behavioral abnormalities), may appear starting from
several years before the diagnosis (prodromal phase) to
later stages of the disease [7, 8]. Rapid eye movement
sleep behavior disorder (RBD), a condition characterised
by acting out of vivid, intense and violent dreams, is a
prodromal marker of PD. [9]
The association between the presence of GBA1 vari-
ants and an increased risk of developing PD was no-
ticed in GD clinics more than 2 decades ago [10, 11].
In addition, the incidence of PD among GD patients
and their relatives, who are carriers of the GBA1 mu-
tation, seem to be higher than in the general popula-
tion [12, 13]. The important role of GBA1 in the
pathogenesis of PD was firmly established when larger
populations of PD patients were screened worldwide
[14]. Several studies confirmed the significantly higher
incidence of GBA1 mutations among PD patients
compared to non-affected subjects in various popula-
tions [15].
GBA1 mutations represent only a predisposing risk
factor for PD. This implies that not every carrier will de-
velop the disease. The reason for this reduced pene-
trance has not yet been fully elucidated. Some authors
have tried to correlate the severity of the mutation with
the age of onset and disease phenotype [16, 17]. How-
ever, the concept of severity of mutation is ambiguous
with respect to GD, as mutation N370S (p.N409S) re-
ported as a mild mutation could be related to severe sys-
temic GD, while mutation L444P (p.L483P), reported as
severe, is associated with a wide spectrum of clinical
phenotypes, including mild GD. Furthermore, the con-
cept of mutation severity is even more controversial in
the field of PD risk because GBA1 variants not associ-
ated with GD (e.g., E326K (p.E365K) and T369M
(p.T408M)), predispose to PD. [18] The reason of such
variability is largely unknown.
Recent evidence suggests that other genetic factors,
such as rare variants in other lysosomal genes, may play
a role in increasing the susceptibility to develop PD in
GBA1 variant carriers, but a definitive role of the contri-
bution of these variants requires further confirmation
and is not yet usable for diagnostic purposes [19]. More-
over, whether PD phenotype in patients with GD differs
from that in heterozygous GBA1 carriers is still unclear.
Nevertheless, it is well known that carriers of GBA1 vari-
ants harbor an increased risk of developing PD that is 5
times higher in heterozygous carriers and 10–20 times
higher in homozygous or compound heterozygous car-
riers, although, these risks vary in different populations
[20, 21].
The issue on how to inform GD patients and their rel-
atives has, so far, been overlooked for various reasons in-
cluding the risk of PD not being high, there are no
biomarkers to better assess the PD risk, there is no ac-
tionable content of the information, the communication
could generate anxiety and stress and information on
sensitive clinical conditions might spread and affect the
subject in some fields as insurance, job and social life.
However, something is changing.
A recent study surveyed subjects with GD for their
knowledge of the increased risk of PD and interest in
learning about it. Most GD patients asked to be in-
formed about PD risk in the clinical setting by the phys-
ician in charge of GD patients at the time of GD
diagnosis together with information concerning other
comorbidities [21]. On the other hand, among PD pa-
tients, there is also a general lack of knowledge regard-
ing the association between GD and PD risk [22].
In a survey involving adults who had GBA1 screening
and did not carry GBA1 variants, the participants indi-
cated with a high level of unanimity that they believe
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that healthcare providers should inform patients about
the increased risk of PD prior to screening. They also
expressed that learning this information would be im-
portant and beneficial and would not cause more anxiety
than receiving news of being a GBA1 carrier alone [23].
From another point of view, GD doctors might be
sued for omitted, retarded, incompleted or potentially
misleading information on PD risk to those who are
potential candidates for future neuroprotective drugs
or who already need a symptomatic treatment for
early symptoms and signs of PD. Some longitudinal
studies on GBA1 variant carriers provide evidence of
a progressive worsening of motor and non-motor pro-
dromal PD features [24, 25]. The identification of
GBA1 variant carriers and the early identification of
subjects, either with mono or biallelic GBA1 muta-
tions, who will develop PD is crucial to address pa-
tients to future neuroprotective drugs or at least to
symptomatic treatments.
In this scenario, we propose a possible approach for
the communication by health care providers to GD pa-
tients about the risk of PD and for management of this
issue.
Methods
The consensus working group was composed of 14 Ital-
ian specialists in internal medicine (n = 2), paediatrics
(n = 5), hematology (n = 5), inborn errors of metabolism
(n = 1) and neurology (n = 1), and are all actively in-
volved in GD management and treatment.
For the first meeting all clinicians received a selected
literature review about PD and GD. During the face-to-
face meeting, all participants agreed that despite exten-
sive literature on epidemiology of PD in subjects with
GD and pathogenesis of PD in GD, scarce data appar-
ently exists about counseling and clinical management
of PD risk in GD patients. A neurologist (ADF) who fol-
lows most Italian patients with GD and PD, as well as
subjects with PD heterozygous for GBA1 variants, re-
ported on his clinical experience and proposed which
symptoms should be asked for early identification of PD.
A pediatrician, also acting as chairman of an institutional
ethics committee, advised on ethical issues concerning
the communication of disease risk to asymptomatic sub-
jects, including minors, and counseling of minors’ par-
ents and caregivers.
The first meeting focused on the following topics:
 Communication of PD risk to adult patients with
GD, to pediatric patients’ parents and caregivers and
to subjects heterozygous for GBA1 variants.
 Management model for early identification of PD by
healthcare providers and referral to neurologists.
The second meeting was a conference call to reach
consensus about some specific points of the two previ-
ously discussed issues. The first manuscript was revised
by all participants and many suggestions were accepted
after being collegially discussed. The final manuscript
was approved by all participants.
Communication of PD risk
In order to align practice with the patient’s preferences,
it is important that GD patients receive the information
on PD risk directly from their healthcare provider rather
than being informed incidentally from websites, without
any appropriate counseling [22]. The healthcare provider
should counsel them, at diagnosis or as soon as possible
during follow-up, about the increased risk of PD. The
patient has the right to refuse to be informed on this
risk. Patients must feel free to ask their physician for in-
formation and to have all doubts and possible misunder-
standings clarified. They need to be reassured that the
physician will eventually provide the necessary support
for an early identification of PD signs and symptoms
and, in case of symptoms affecting the quality of life, for
an early therapeutic approach.
According to the current clinical practice, the phys-
ician should adapt the communication of the PD risk to
the social and cultural background of GD patients or
parents of underage GD patients. The communication
should state clearly that the lifetime risk to develop PD
affects both patients and heterozygous carriers, with the
GD patients having a higher risk and an earlier onset
compared to the heterozygous carriers. All GD patients
who have been diagnosed before the emerging evidence
of GBA1 as a PD risk factor must receive this informa-
tion as soon as possible.
Being the issue of the risk for PD among GD patients
still an area of active investigation, the healthcare pro-
viders should keep uptodate on this issue.
In case of GD diagnosis in an underage patient, par-
ents should be informed at the time of the diagnosis
about the increased risk of PD. However, since the PD
onset rarely occurs before 40 years of age, it is inappro-
priate to inform the child. The information should be
postponed to a later age, after transition from paediatric
to an adult clinical setting and provided by the health-
care provider for adult patients. At the time of GD diag-
nosis in a young underage patient, if the status of
heterozygous is confirmed in the parents, a genetic
counselor should inform them of an increased PD risk
(Fig. 1).
The panel reached consensus that the expanded famil-
ial screening to identify subjects carrying GBA1 variants
with an increased risk of PD is probably not justified be-
cause of the overall low risk of PD. However, patients or
parents should be invited to decide whether to share
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with their relatives the information on the PD risk and
the possibility for them to undergo genetic testing for
GBA1, since this procedure does not seem to violate the
principles of non-maleficence and justice. It is the duty
of the physicians to offer information to the patients/
parents to make a decision which respects their rights
but also their relatives’ rights.
Genetic testing is offered frequently to couples of Ash-
kenazi Jewish ancestry, in the context of genetic counsel-
ing, since GBA1 pathogenic variants are known to be
frequent in that population. For these subjects it is ap-
propriate to give the information about the increased PD
risk, both for the GD offspring and for themselves, if
they are GD heterozygotes.
Management of PD risk
PD patients with GD or heterozygous for GBA1 variants
do not show specific features that would clearly distin-
guish them from patients with idiopathic PD. [17] How-
ever, the onset of PD is in average earlier in both
heterozygous carriers and in subjects with GD, com-
pared to the general population [12, 26].
PD patients with GD or heterozygotes for a GBA1 vari-
ant have a risk to develop dementia up to 3 times higher
than patients with idiopathic PD. Hallucinations and
RBDs are more common in GBA1 PD patients, whereas
there is no consensus yet on the frequency of other non-
motor symptoms, such as anosmia, depression, anxiety,
constipation, urinary symptoms, orthostatic hypotension
Fig. 1 Communication of PD risk to GD patients and their relatives who are GBA1 heterozygote mutation carriers
Fig. 2 Early Motor Signs and Non-Motor Symptoms/Signs of PD
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and sexual dysfunctions. Increased incidence of dysauto-
nomia and motor complications, such as dysphagia, dys-
arthria and freezing of gait, is reported in GBA1 PD
patients compared to idiopathic PD patients [12, 26].
Based on these data, the working group reached the fol-
lowing consensus concerning management of PD risk in
GD patients:
– From the age of 35–40 years, every 12 months,
healthcare providers should monitor the patient’s
clinical history concerning non-motor and motor
symptoms/signs suggestive of PD (Fig. 2) and to
evaluate the patient for motor signs.
– The patient might be referred to neurologists when
presenting with at least one clear motor sign alone
or in the presence of any non-motor symptoms/
signs with impact on the quality of life (Fig. 2).
Conclusion
The risk for PD among GD carriers and affected individ-
uals is still an area of active investigation.
However, according to current knowledge, we propose
an evidence-informed practical guidance to communica-
tion, counseling and management of PD risk in GD pa-
tients. It is essential that healthcare providers with the
updated evidence-based knowledge on this issue com-
municate the risk of developing PD to adult carriers of
GBA1 variants (either GD patients or their relatives who
are heterozygous carriers), taking into account the cul-
tural and emotional characteristics of each individual
and their will to be informed.
Furthermore, this resource will help to empower health-
care providers to identify early signs and/or symptoms of
PD and to decide when to refer these patients to the neur-
ologist for appropriate specific therapy and follow-up.
A hopeful future and availability of neuroprotective
therapies may influence the way in which we inform GD
patients and GBA1 variant carriers on their PD risk and
will, therefore, require a new reflection on how to deal
with the delicate issue of communicating the risk of this
neurodegenerative disease.
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